Congr. Surface Activity, Proc. 2nd, I, 353(1957) and references cited therein.

(3) L. Sjöblom, in "Solvent Properties of Surfactant Solutions," K. Shinoda, Ed., Marcel Dekker, New York, N. Y., 1967, p. 221, and references cited therein.

(4) A. L. Thakkar and P. B. Kuehn, J. Pharm. Sci., 58, 850 (1969).

(5) J. L. Lach and W. A. Pauli, *ibid.*, 55, 32(1966).

(6) T. R. Bates, M. Gibaldi, and J. L. Kanig, *ibid.*, 55, 191(1966).
(7) D. M. Small, in "Molecular Association in Biological and Related Systems," R. F. Gould, Ed., Advances in Chemistry Series, Monograph No. 84, Amer. Chem. Soc., Washington, D. C., 1968, p. 31.

(8) D. M. Small, S. A. Penkett, and D. Chapman, *Biochim. Biophys. Acta*, **176**, 178(1969).

(9) D. M. Small and W. Admirand, Nature, 221, 265(1969).

ACKNOWLEDGMENTS AND ADDRESSES

Received November 17, 1969, from the Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, IN 46206

Accepted for publication March 17, 1970.

The author acknowledges the technical assistance of W. L. Wilham and P. B. Kuehn in carrying out portions of the laboratory work.

Alkaloids of Tylophora I: Isolation of Six New Alkaloids

KOPPAKA V. RAO*, RICHARD WILSON, and BERNICE CUMMINGS

Abstract \Box Tylophora crebriflora (N. O. Asclepiadaceae) is a slender vine found chiefly in northeastern Australia. In a detailed examination of the plant, six alkaloids have been isolated which have not previously been shown to be present in this genus. The methods for their isolation and their physical characteristics are described.

Keyphrases \Box *Tylophora crebriflora*—separation, isolation, physical properties, six alkaloids \Box IR spectrophotometry—structure, identification \Box UV spectrophotometry—structure, identification

In a series of papers during the 1950's, Govindachari et al. (1-5) described the isolation, structure, and synthesis of two alkaloids, tylophorine and tylophorinine, present in the Indian plant Tylophora indica. These alkaloids are built up of a dibenzo[f,h]-pyrrolo[1,2b]isoquinoline skeleton. From a related Australian plant, Tvlophora crebriflora. Gellert et al. (6) described the isolation of a third member named tylocrebrine, together with a minor amount of tylophorine. The two were shown to be isomeric, differing in the arrangement of the methoxyl groups. During routine screening by the Cancer Chemotherapy National Service Center (CCNSC), it was observed that tylocrebrine showed significant antileukemic activity. At the request of CCNSC to provide tylocrebrine for possible clinical trials, these studies were initiated.

EXPERIMENTAL

The dried plant, *Tylophora crebriflora*, was obtained from Australia.¹ The total alkaloid fraction could be readily isolated by the following steps: (a) extraction with 1% methanolic acetic acid;



Scheme I—Separation of the alkaloids of Tylophora crebriflora. System 1: 3% aqueous acetic acid-chloroform-ethyl acetate (10:7:3) System 2: 3% aqueous acetic acid-chloroform-n-butanol (5:4:1)

(b) concentration; (c) partition between ethyl acetate and 0.2 N HCl (aq.); and (d) extraction of the aqueous layer at pH 9–10 with chloroform. The crude mixture of alkaloids represented a yield of approximately 0.15%.

The mixture was separated into its components by the use of countercurrent distribution and chromatography on a commercial adsorbent,² as indicated in Scheme I. In addition to the two known members, tylocrebrine and tylophorine, the extracts yielded six new alkaloids.

Tylocrebrine and Alkaloid A are the major components, each being present to the extent of about 40% of the total. Next in abundance are tylophorine and Alkaloids B and C, which account for approximately 4-5% each. The rest is made up of the other three members, Alkaloids D, E, and F.

The analytical data and physical properties of the new members are shown in Tables I and II. In general, Alkaloids A-E show

¹ The plant material used in this study was collected, identified, and supplied by the Department of Forestry of Queensland, Brisbane, Queensland, Australia, in 1964. (A voucher specimen was preserved at Chas. Pfizer & Co., Inc., Maywood, N. J.)

² Florisil, Floridin Co., Pittsburgh, Pa.

Table I-Characteristics of the Tylophora Alkaloids

Property		Alkaloid A		Alkaloid B		Alkaloid C	
1.	Melting point	212–214°		222–224°		223-225°	
2.	Formula	$C_{24}H_{27}NO_5$		$C_{23}H_{25}NO_4$		$C_{23}H_{25}NO_5$	
3.	Analysis	Calcd. C, 70.40 H, 6.65 N, 3.42 OMe, 30.31	Found C, 70.26 H, 6.62 N, 3.43 OMe, 30.16	Calcd. C, 72.80 H, 6.64 N, 3.69 OMe, 24.53	Found C, 72.41 H, 6.69 N, 3.61 OMe, 24.49	Calcd. C, 69.85 H, 6.37 N, 3.54 OMe, 23.07	Found C, 69.42 H, 6.44 N, 3.55 OMe, 23.54
4.	UV spectrum	λ_{max} . 262 285(sh) 305(sh)	log ε 4.837 4.425 4.028	λ_{max} . 262 284(sh) 302(sh)	log ε 4.818 4.386 4.057	λ_{max} . 262 265(sh) 303(sh)	log ε 4.777 4.359 4.143
5.	Rotation $[\alpha]_{D}^{25}$ (C, 1 in chloroform)	-32		63		34	
6.	<i>R_f</i> : Citric acid–formamide– chloroform ^a Formamide–chloroform	0.2-0.3 0.65-0.75		0-0.1 0.5-0.6		0-0.1 0.3-0.4	

^a Whatman No. 1 sheets immersed in 5% citric acid, dried, moistened before use with 30% formamide in methanol, and developed with chloroform saturated with formamide.

Table II-Characteristics of the Tylophora Alkaloids

	Property	Alkaloid	D	Alkaloid	E	Alka	loid F
1.	Melting point	186–188°		198-200°		137–138°	
2.	Formula	$C_{25}H_{29}NO_{6}$		$C_{25}H_{29}NO_5$		$C_{24}H_{29}NO_{4}$	
3. 4.	Analysis UV spectrum	Calcd. C, 68.32 C H, 6.65 H N, 3.19 N OMe, 35.30 O λ_{max} . 262 282(sh)	Found , 68.36 , 6.80 , 3.19 Me, 34.95 log ϵ 4.843 4.410	Calcd. C, 70.90 C, H, 6.80 H N, 3.31 N OMe, 36.64 O λ_{max} . 263	Found , 70.67 , 6.80 , 3.88 Me, 36.21 $\log \epsilon$ 4.878	Calcd. C, 72.88 H, 7.39 N, 3.54 OMe, 31.39 λ_{max} . 240(sh) 288	Found C, 72.74 H, 7.37 N, 3.52 OMe, 31.40 $\log \epsilon$ 4.198 4.001
5. 6.	Rotation $[\alpha]_{D}^{25}$ R_{f} : Citric acid-formamide- chloroform	- 16.5 0.4-0.5		- 69 0.7-0.8		42.5 0.7-0.8	

characteristics very similar to those of tylocrebrine, thus showing similarity in chemical structure. Alkaloid F has somewhat different spectral properties, and the exact significance of these results will be discussed in a subsequent paper.

REFERENCES

(1) T. R. Govindachari, B. R. Pai, and K. Nagarajan, J. Chem. Soc., 1954, 2801.

(2) T. R. Govindachari, M. V. Lakshmikantham, K. Nagarajan, and B. R. Pai, *Tetrahedron*, 4, 311(1958).

(3) T. R. Govindachari, M. V. Lakshmikantham, K. Nagarajan, and B. R. Pai, *Chem. Ind.*, **1957**, 1484.

(4) T. R. Govindachari, M. V. Lakshmikantham, B. R. Pai, and S. Rajappa, *Tetrahedron*, 9, 53(1960).

(5) T. R. Govindachari, B. R. Pai, S. Rajappa, and N. Viswanathan, *Chem. Ind.*, **1959**, **950**. (6) E. Gellert, T. R. Govindachari, M. V. Lakshmikantham, I. S. Ragade, R. Rudzats, and N. Viswanathan, J. Chem. Soc., **1962**, 1008.

(7) E. Gellert and R. Rudzats, J. Med. Chem., 7, 361(1964).

ACKNOWLEDGMENTS AND ADDRESSES

Received December 8, 1969, from *The John L. Smith Memorial* for Cancer Research, Chas. Pfizer & Co., Inc., Maywood, NJ 07607

Accepted for publication May 11, 1970.

This investigation was supported by Contract PH43-68-45 from the Cancer Chemotherapy National Service Center, National Institutes of Health, U. S. Public Health Service.

* To whom correspondence should be addressed. Present address: College of Pharmacy, University of Florida, Gainesville, FL 32601